Project Grant R01CA311659
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $675K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $693,403 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded June 9, 2026, with completion targeted for May 31, 2031. The award funds research to identify and inhibit novel downstream effectors of mutant RAS (KRAS) for cancer treatment development. The project addresses a critical gap in current oncology therapeutics: while KRAS is the...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $1.3 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through May 31, 2030, to develop highly tumor-selective pan RAS inactivators for targeting oncogenic RAS-driven cancers. The project addresses a critical unmet medical need by engineering a novel therapeutic approach that combines the anthrax toxin protein delivery system with DUF5...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $682,673 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for research on "Adaptation and Evolution of Resistance to Pan-RAS Inhibition in Pancreatic Ductal Adenocarcinoma." The five-year project, spanning May 1, 2026 through April 30, 2031, supports fundamental and applied research investigating mechanisms of tumor resistance to pan-RAS...
- Summary The University of California, San Francisco (UCSF) received a $636,345 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. This five-year research initiative will characterize the molecular mechanisms governing phosphoinositide 3-kinase alpha (PI3KA) activation at the cellular membrane, specifically examining how RAS proteins and receptor tyrosine kinases (RTKs) converge to activate...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $700,338 to the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) on May 11, 2026, with an expected completion date of April 30, 2031. This Project Grant funds research to identify and validate resistance mechanisms to asciminib, the first allosteric tyrosine kinase inhibitor (TKI) approved for chronic myeloid leukemia (CML) treatment. The research addresses a critical clinical...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $411,152 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 5, 2025, with completion targeted for August 31, 2027. This research initiative focuses on identifying and validating noncovalent protein interactions of mutant KRAS (MKRAS) inhibitors, addressing a critical gap in understanding off-target effects of recently FDA-approved...
- Federal Grant Award Summary New York University School of Medicine received a $435,827 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 4, 2025, with completion targeted for May 31, 2027. The grant supports research entitled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," which investigates combination therapeutic strategies to overcome intrinsic and emergent resistance to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $680,597 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for the period April 1, 2026 through March 31, 2031. This award funds fundamental research to develop and execute genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) loss-of-function screens in human T cells to identify gene targets that enhance...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $640,466 Project Grant to The Regents of the University of California, San Francisco for the development of covalent protein radiopharmaceuticals for targeted radionuclide therapy in cancer treatment. The award, which commenced June 1, 2026 and extends through May 31, 2031, supports research under the Cancer Treatment Research program (CFDA 93.395). The project focuses on bioengineering low molecular weight proteins with...